{"title": "Semaglutide", "page_id": 50133223, "revision_id": 1130544161, "revision_timestamp": "2022-12-30T18:18:50Z", "content": "{{Short description|Chemical compound (anti-diabetic medication)}}\n{{Use dmy dates|date=December 2022}}\n{{Infobox drug\n| drug_name          = \n| INN                = \n| type               = <!-- empty -->\n| image              = Semaglutide.svg\n| width              = 300\n| alt                = \n| caption            =\n\n<!-- Clinical data -->\n| pronounce          = \n| tradename          = Ozempic, Rybelsus, Wegovy, others\n| Drugs.com          = {{Drugs.com|monograph|semaglutide}}\n| MedlinePlus        = a618008\n| licence_EU         = yes\n| DailyMedID         = Semaglutide\n| licence_US         = <!-- FDA may use generic or brand name (generic name preferred) -->\n| pregnancy_AU       = D\n| pregnancy_AU_comment = <ref name=\"AusPAR: Semaglutide\" /><ref name=\"Rybelsus APMDS\">{{cite web |date=22 February 2022 |title=Rybelsus APMDS |url=https://www.tga.gov.au/resources/auspmd/rybelsus |access-date=23 February 2022 |website=Therapeutic Goods Administration (TGA)}}</ref>\n| pregnancy_category = \n| routes_of_administration = [[Subcutaneous injection|Subcutaneous]], [[Oral administration|by mouth]]\n| class              = \n| ATCvet             = \n| ATC_prefix         = A10\n| ATC_suffix         = BJ06\n| ATC_supplemental  =\n\n<!-- Legal status -->\n| legal_AU           = S4\n| legal_AU_comment   = <ref name=\"AusPAR: Semaglutide\" /><ref name=\"TGA Ozempic\" /><ref name=\"Rybelsus APMDS\" /><ref>{{cite web |title=Summary for ARTG Entry: 346198 Rybelsus semaglutide 3 mg tablet blister pack |url=https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=346198 |url-status=live |archive-url=https://web.archive.org/web/20220224072337/https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=346198 |archive-date=24 February 2022 |access-date=23 February 2022 |website=Therapeutic Goods Administration (TGA)}}</ref>\n| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->\n| legal_BR_comment  = \n| legal_CA           = Rx-only\n| legal_CA_comment  = /{{nbsp}}Schedule D<ref>{{cite report |url=https://pdf.hres.ca/dpd_pm/00058023.PDF |title=Product Monograph Including Patient Medication Information \u2013 Ozempic semaglutide injection |date=21 August 2020 |publisher=Novo-Nordisk Canada |access-date=6 June 2021 |archive-url=https://web.archive.org/web/20210607034549/https://pdf.hres.ca/dpd_pm/00058023.PDF |archive-date=7 June 2021 |url-status=live |orig-date=Initial approval 4 January 2018}}</ref><ref>{{cite report |url=https://pdf.hres.ca/dpd_pm/00055582.PDF |title=Product Monograph Including Patient Medication Information \u2013 Rybelsus semaglutide tablets |date=30 March 2020 |publisher=Novo-Nordisk Canada |access-date=6 June 2021 |archive-url=https://web.archive.org/web/20211214093723/https://pdf.hres.ca/dpd_pm/00055582.PDF |archive-date=14 December 2021 |url-status=live}}</ref><ref>{{cite web |date=23 October 2014 |title=Regulatory Decision Summary \u2013 Rybelsus |url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00625 |url-status=live |archive-url=https://web.archive.org/web/20220605060327/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00625 |archive-date=5 June 2022 |access-date=4 June 2022 |website=Health Canada}}</ref>\n| legal_DE           = <!-- Anlage I, II, III -->\n| legal_DE_comment  = \n| legal_NZ           = <!-- Class A, B, C -->\n| legal_NZ_comment  = \n| legal_UK           = POM\n| legal_UK_comment  = <ref>{{cite web |date=9 April 2021 |title=Ozempic 0.25 mg solution for injection in pre-filled pen \u2013 Summary of Product Characteristics (SmPC) |url=https://www.medicines.org.uk/emc/product/9748/smpc |url-status=live |archive-url=https://web.archive.org/web/20210606181424/https://www.medicines.org.uk/emc/product/9748/smpc |archive-date=6 June 2021 |access-date=6 June 2021 |website=(emc)}}</ref><ref>{{cite web |date=25 November 2020 |title=Rybelsus \u2013 Summary of Product Characteristics (SmPC) |url=https://www.medicines.org.uk/emc/product/11507/smpc |url-status=live |archive-url=https://web.archive.org/web/20210606181424/https://www.medicines.org.uk/emc/product/11507/smpc |archive-date=6 June 2021 |access-date=6 June 2021 |website=(emc)}}</ref>\n| legal_US           = Rx-only\n| legal_US_comment  = <ref name=\"Ozempic FDA label\" /><ref name=\"Rybelsus FDA label\" /><ref name=\"Wegovy FDA label\" />\n| legal_EU           = Rx-only\n| legal_EU_comment   = <ref name=\"Ozempic EPAR\" /><ref name=\"Rybelsus EPAR\" /><ref name=\"Wegovy EPAR\" />\n| legal_UN           = <!-- N I, II, III, IV / P I, II, III, IV-->\n| legal_UN_comment  = \n| legal_status       = Rx-only\n\n<!-- Pharmacokinetic data -->\n| bioavailability    = 89%\n| protein_bound      = \n| metabolism         = [[Proteolysis]]\n| metabolites        = \n| onset              = \n| elimination_half-life = 7 days\n| duration_of_action = 63.6 h\n| excretion          = Urine and feces\n\n<!-- Identifiers -->\n| CAS_number         = 910463-68-2\n| CAS_supplemental  = \n| PubChem            = 56843331\n| IUPHAR_ligand     = \n| DrugBank           = DB13928\n| ChemSpiderID       = 34981134\n| UNII               = 53AXN4NNHX\n| KEGG               = D10025\n| ChEBI             = \n| ChEMBL            = \n| NIAID_ChemDB      = \n| PDB_ligand        = \n| synonyms          =\n\n<!-- Chemical and physical data -->\n| IUPAC_name        = \n| C = 187 | H = 291 | N = 45 | O = 59\n| SMILES             = CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC6=CN=CN6)N\n| StdInChI           = 1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1\n| StdInChI_comment  = \n| StdInChIKey        = DLSWIYLPEUIQAV-CCUURXOWSA-N\n| StdInChIKey_Ref    = {{stdinchicite|correct|pubchem}}\n| density           = \n| density_notes     = \n| melting_point     = \n| melting_high      = \n| melting_notes     = \n| boiling_point     = \n| boiling_notes     = \n| solubility        = \n| sol_units         = \n| specific_rotation = \n}}\n<!-- Definition and uses -->\n'''Semaglutide''', sold under the brand names '''Ozempic''', '''Wegovy''' and '''Rybelsus''', is an [[antidiabetic medication]] used for the treatment of [[type 2 diabetes]] and as [[anti-obesity medication]] for long-term [[weight management]], developed by Novo Nordisk in 2012.<ref>{{cite web |title=Semaglutide Approval Status |url=https://www.drugs.com/history/semaglutide.html |url-status=live |archive-url=https://web.archive.org/web/20171024205830/https://www.drugs.com/history/semaglutide.html |archive-date=24 October 2017 |access-date=18 May 2017 |publisher=[[drugs.com]]}}</ref><ref>{{cite press release |title=Ozempic (semaglutide) approved in the US |date=5 December 2017 |url=https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=712 |access-date=5 June 2021 |url-status=live |archive-url=https://web.archive.org/web/20210605223522/https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=712 |archive-date=5 June 2021 |website=Novo Nordisk}}</ref><ref name=\"FDA Wegovy PR 20210604\">{{cite press release |title=FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 |date=4 June 2021 |url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 |access-date=5 June 2021 |url-status=live |archive-url=https://web.archive.org/web/20210604235421/https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 |archive-date=4 June 2021 |website=U.S. [[Food and Drug Administration]] (FDA)}}</ref>\n{{medcn|date=October 2022}}\n\n<!-- Mechanism and adverse effects -->\nSemaglutide is a [[GLP-1 receptor agonist]], meaning that it mimics the action of the human [[incretin]] [[glucagon-like peptide-1]] (GLP-1), thereby increasing [[insulin]] secretion and increasing [[blood sugar]] disposal and improving [[glycemic control]]. Side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.<ref name=\"Ozempic FDA label\" />\n\n<!-- Society and culture -->\nIn December 2017, the injectable version named Ozempic was approved, in September 2019, a version which can be taken by mouth (Rybelsus) was approved, <ref name=\"FDA2019\">{{cite press release |title=FDA approves first oral GLP-1 treatment for type 2 diabetes |date=20 September 2019 |publisher=FDA |url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes |access-date=20 September 2019 |url-status=live |archive-url=https://web.archive.org/web/20190923102804/https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes |archive-date=23 September 2019}}</ref> and in June 2021, a higher-dose injection sold under the brand name Wegovy for long-term weight management in adults was approved by the US [[Food and Drug Administration]] (FDA).<ref name=\"Wegovy FDA label\">{{cite web |date=4 June 2021 |title=Wegovy- semaglutide injection, solution |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b |url-status=live |archive-url=https://web.archive.org/web/20211214080941/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b |archive-date=14 December 2021 |access-date=11 March 2022 |website=DailyMed}}</ref>\n\nIn 2020, semaglutide was the 129th most commonly prescribed medication in the United States, with more than 4{{nbsp}}million prescriptions.<ref>{{cite web |title=The Top 300 of 2020 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |access-date=7 October 2022 |website=ClinCalc}}</ref><ref>{{cite web |title=Semaglutide - Drug Usage Statistics |url=https://clincalc.com/DrugStats/Drugs/Semaglutide |access-date=7 October 2022 |website=ClinCalc}}</ref>\n\n==Medical uses==\nSemaglutide is [[Indication (medicine)|indicated]] as an adjunct to diet and exercise to improve [[glycemic control]] in adults with [[type 2 diabetes]].<ref name=\"Ozempic FDA label\">{{cite web |title=Ozempic- semaglutide injection, solution |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 |url-status=live |archive-url=https://web.archive.org/web/20210605224054/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 |archive-date=5 June 2021 |access-date=5 June 2021 |website=DailyMed}}</ref><ref name=\"Rybelsus FDA label\">{{cite web |title=Rybelsus- oral semaglutide tablet |url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 |url-status=live |archive-url=https://web.archive.org/web/20210605223601/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 |archive-date=5 June 2021 |access-date=5 June 2021 |website=DailyMed}}</ref>\n\nSemaglutide is also indicated as an adjunct to diet and exercise for long-term weight management in adults with [[obesity]] (initial [[body mass index]] (BMI) \u2265 30&nbsp;kg/m<sup>2</sup>) or overweight (initial BMI \u2265 27&nbsp;kg/m<sup>2</sup>) with at least one weight-related comorbidity.<ref name=\"Wegovy FDA label\" /><ref name=\"Wegovy EPAR\" /><ref name=\"FDA Wegovy PR 20210604\" />\n\nA review of anti-obesity treatments found that semaglutide as well as [[tirzepatide]] which has an overlapping mechanism of action were more promising than previous anti-obesity drugs, although less effective than [[bariatric surgery]].<ref>{{cite journal |vauthors=M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD |date=March 2022 |title=Anti-obesity drug discovery: advances and challenges |journal=Nature Reviews. Drug Discovery |volume=21 |issue=3 |pages=201\u2013223 |doi=10.1038/s41573-021-00337-8 |pmc=8609996 |pmid=34815532 |doi-access=free |title-link=doi }}</ref>\n\n==Adverse effects==\nSide effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.<ref name=\"Ozempic FDA label\" /> In people with heart problems, it can cause damage to the retina of the eye ([[retinopathy]]).<ref name=\"doggrell\" /> Other, less common side effects include kidney problems, allergic reactions, low blood sugar, and [[pancreatitis]].<ref name=\"FDA2019\" />\n\n== Contraindications ==\nDue to data from rodents studies of GLP-1-mediated thyroid [[Thyroid C cell tumor|C-cell hyperplasia]],<ref>{{cite journal |last1=Bjerre Knudsen |first1=Lotte |last2=Madsen |first2=Lars Wichmann |last3=Andersen |first3=S\u00f8ren |last4=Almholt |first4=Kasper |last5=de Boer |first5=Anne S. |last6=Drucker |first6=Daniel J. |last7=Gotfredsen |first7=Carsten |last8=Egerod |first8=Frederikke Lihme |last9=Hegelund |first9=Anne Charlotte |last10=Jacobsen |first10=Helene |last11=Jacobsen |first11=S\u00f8ren Dyring |last12=Moses |first12=Alan C. |last13=M\u00f8lck |first13=Anne-Marie |last14=Nielsen |first14=Henriette S. |last15=Nowak |first15=Jette | display-authors=6 |date=April 2010 |title=Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation |journal=Endocrinology |volume=151 |issue=4 |pages=1473\u20131486 |doi=10.1210/en.2009-1272 |pmid=20203154 |s2cid=20934882 | doi-access=free | title-link=doi | name-list-style=vanc }}</ref> the use is contraindicated in people with a personal or family history of medullary thyroid carcinoma and in patients with [[Men2|multiple endocrine neoplasia syndrome type 2]].<ref name=\"Rybelsus FDA label\" /><ref name=\"Ozempic FDA label\" />\n\n==Mechanism of action==\nSemaglutide is a [[glucagon-like peptide-1]] receptor agonist. By mimicking the action of the [[incretin]] GLP-1, it increases the production of [[insulin]], the hormone which lowers the [[blood sugar level]].<ref>{{cite journal |vauthors=Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T | display-authors=6 |date=November 2016 |title=Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes |journal=The New England Journal of Medicine |volume=375 |issue=19 |pages=1834\u20131844 |doi=10.1056/NEJMoa1607141 |pmid=27633186 |doi-access=free |title-link=doi }}</ref> It appears to enhance growth of pancreatic [[beta cells]], which are responsible for insulin production and release.<ref name=\"goldenberg\" /><ref>{{cite journal |vauthors=Li Y, Hansotia T, Yusta B, Ris F, Halban P, Drucker D |date=2003 |title=Glucagon-like Peptide-1 Receptor Signaling Modulates \u03b2 Cell Apoptosis |journal=The Journal of Biological Chemistry |volume=278 |issue=1 |pages=471\u2013478 |doi=10.1074/jbc.M209423200 |pmid=12409292 |doi-access=free |title-link=doi }}</ref> It also inhibits the production of [[glucagon]], the hormone that increases [[glycogenolysis]] (release of stored carbohydrate from the liver) and [[gluconeogenesis]] (synthesis of new glucose). It reduces food intake by lowering appetite and slowing down digestion in the stomach,<ref name=\"doggrell\">{{cite journal |vauthors=Doggrell SA |date=March 2018 |title=Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? |url=https://eprints.qut.edu.au/121664/2/121664.pdf |url-status=live |journal=Expert Opinion on Drug Metabolism & Toxicology |volume=14 |issue=3 |pages=371\u2013377 |doi=10.1080/17425255.2018.1441286 |pmid=29439603 |archive-url=https://web.archive.org/web/20200505082922/https://eprints.qut.edu.au/121664/2/121664.pdf |archive-date=5 May 2020 |access-date=12 December 2019 |s2cid=3421553}}</ref> helping to reduce body fat.<ref name=\"dhillon\">{{cite journal |vauthors=Dhillon S |date=February 2018 |title=Semaglutide: First Global Approval |journal=Drugs |volume=78 |issue=2 |pages=275\u2013284 |doi=10.1007/s40265-018-0871-0 |pmid=29363040 |s2cid=46851453}}</ref> It reduces hunger, food craving and body fat.<ref>{{cite news |date=23 October 2017 |title=Drug can dramatically reduce weight of people with obesity |work=ScienceDaily |url=https://www.sciencedaily.com/releases/2017/10/171023131955.htm |url-status=live |access-date=24 October 2017 |archive-url=https://web.archive.org/web/20190715180929/https://www.sciencedaily.com/releases/2017/10/171023131955.htm |archive-date=15 July 2019}}</ref><ref>{{cite journal | vauthors = Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB | display-authors = 6 | title = Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity | journal = Diabetes, Obesity & Metabolism | volume = 19 | issue = 9 | pages = 1242\u20131251 | date = September 2017 | pmid = 28266779 | pmc = 5573908 | doi = 10.1111/dom.12932 | doi-access = free | title-link = doi }}</ref>\n\n==Pharmacology==\nSemaglutide is chemically similar to human GLP-1, with 94% similarity. The only differences are two amino-acid substitutions at positions 8 and 34, where alanine and lysine are replaced by [[2-aminoisobutyric acid]] and arginine, respectively.<ref>{{cite journal |vauthors=Lau J, Bloch P, Sch\u00e4ffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T | display-authors=6 |date=September 2015 |title=Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide |journal=Journal of Medicinal Chemistry |volume=58 |issue=18 |pages=7370\u201380 |doi=10.1021/acs.jmedchem.5b00726 |pmid=26308095 |s2cid=20228358}}</ref> Amino-acid substitution at position 8 prevents chemical breakdown by dipeptidyl peptidase-4. In addition, the lysine at position 26 is in its derivative form (acylated with [[stearic acid|stearic diacid]]). Acylation with a spacer and C-18 fatty diacid chain increases the drug's binding to blood protein (albumin), which enables longer presence in the blood circulation.<ref>{{cite journal |vauthors=Gotfredsen CF, M\u00f8lck AM, Thorup I, Nyborg NC, Salanti Z, Knudsen LB, Larsen MO | display-authors=6 |date=July 2014 |title=The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates |journal=Diabetes |volume=63 |issue=7 |pages=2486\u201397 |doi=10.2337/db13-1087 |pmid=24608440 |doi-access=free |title-link=doi |s2cid=35102048}}</ref>\n\nIts half-life in the blood is about seven days (165\u2013184 hours).<ref name=\"goldenberg\">{{cite journal |vauthors=Goldenberg RM, Steen O |date=March 2019 |title=Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes |journal=Canadian Journal of Diabetes |volume=43 |issue=2 |pages=136\u2013145 |doi=10.1016/j.jcjd.2018.05.008 |pmid=30195966 |doi-access=free |title-link=doi }}</ref><ref name=\"kapitza\">{{cite journal |vauthors=Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A |date=May 2015 |title=Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel |journal=Journal of Clinical Pharmacology |volume=55 |issue=5 |pages=497\u2013504 |doi=10.1002/jcph.443 |pmc=4418331 |pmid=25475122}}</ref> It can be administered by subcutaneous injection once weekly or once-daily by mouth. No significant difference in the decrease from baseline body weight was observed between groups taking it orally (20 mg and 40-mg) or subcutaneously.<ref>{{cite journal |vauthors=Davies M, [[Thomas Pieber|Pieber TR]], Hartoft-Nielsen ML, Hansen OK, Jabbour S, Rosenstock J |date=October 2017 |title=Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial |journal=JAMA |volume=318 |issue=15 |pages=1460\u20131470 |doi=10.1001/jama.2017.14752 |pmc=5817971 |pmid=29049653}}</ref>\n\n==History==\nIn 2012, a team of researchers at [[Novo Nordisk]] developed Semaglutide<ref>{{cite journal |date=October 2012 |title=Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1-5, 2012. Berlin, Germany |journal=Diabetologia |volume=55 |issue=S1 |pages=S7-537 |doi=10.1007/s00125-012-2688-9 |pmid=22918257 |doi-access=free |title-link=doi }}</ref> for a once-weekly diabetes therapy as a longer-acting alternative to [[liraglutide]].<ref>{{cite journal |vauthors=Kalra S, Gupta Y |date=July 2015 |title=Once-weekly glucagon-like peptide 1 receptor agonists |url=https://jpma.org.pk/article-details/7416?article_id=7416 |url-status=live |journal=The Journal of the Pakistan Medical Association |volume=65 |issue=7 |pages=796\u20138 |pmid=26160096 |archive-url=https://web.archive.org/web/20220930044839/https://jpma.org.pk/article-details/7416?article_id=7416 |archive-date=30 September 2022 |access-date=10 April 2022}}</ref> It was given the brand name Ozempic. Clinical trials were started in January 2016, and completed in May 2017.<ref>{{ClinicalTrialsGov|NCT02648204|Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes}}</ref>{{Full citation needed|date=December 2022}}\n\nIn 2017, researchers at the [[University of Leeds]] and Novo Nordisk reported that it could also be used for the treatment of [[obesity]].<ref name=\"blundell17\">{{cite journal |vauthors=Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB | display-authors=6 |date=September 2017 |title=Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity |journal=Diabetes, Obesity & Metabolism |volume=19 |issue=9 |pages=1242\u20131251 |doi=10.1111/dom.12932 |pmc=5573908 |pmid=28266779}}</ref> In March 2021, a phase 3 randomized controlled trial found that once-weekly injection of 2.4&nbsp;mg of the drug resulted in an average change of \u221215% body weight at 68 weeks compared to \u22122% for the placebo.<ref>{{cite journal |vauthors=Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF | display-authors=6 |date=March 2021 |title=Once-Weekly Semaglutide in Adults with Overweight or Obesity |journal=New England Journal of Medicine |volume=384 |issue=11 |pages=989\u20131002 |doi=10.1056/NEJMoa2032183 |pmid=33567185 |s2cid=231883214 |doi-access=free |title-link=doi }}</ref>\n\n== Society and culture ==\n=== Legal status ===\nIn December 2016, the US FDA [[New Drug Application]] (NDA) was filed, and in October 2017, the FDA Advisory Committee approved it unanimously.<ref>{{cite news |date=2017 |title=Development Status and FDA Approval Process for semaglutide |work=Drugs.com |url=https://www.drugs.com/history/semaglutide.html |url-status=live |access-date=24 October 2017 |archive-url=https://web.archive.org/web/20171024205830/https://www.drugs.com/history/semaglutide.html |archive-date=24 October 2017}}</ref>\n\nIn December 2017, the injectable version with the brand name Ozempic was approved for medical use in the United States,<ref name=\"Ozempic FDA approval\">{{cite web |date=16 January 2018 |title=Drug Approval Package: Ozempic (semaglutide) Injection |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209637Orig1s000TOC.cfm |url-status=live |archive-url=https://web.archive.org/web/20210301022302/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209637Orig1s000TOC.cfm |archive-date=1 March 2021 |access-date=26 September 2020 |publisher=U.S. [[Food and Drug Administration]] (FDA)}}</ref> and in January 2018 in Canada,<ref name=\"CA approval\">{{cite web |date=23 October 2014 |title=Regulatory Decision Summary \u2013 Ozempic |url=https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00317 |url-status=live |archive-url=https://web.archive.org/web/20190517173304/https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00317 |archive-date=17 May 2019 |access-date=2 April 2019 |publisher=Health Canada}}</ref>\n\nIn February 2018, authorization was granted in the European Union,<ref name=\"Ozempic EPAR\">{{cite web |title=Ozempic EPAR |url=https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic |url-status=live |archive-url=https://web.archive.org/web/20201025204658/https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic |archive-date=25 October 2020 |access-date=26 September 2020 |publisher=[[European Medicines Agency]] (EMA)}}</ref> <ref name=\"EU\">{{cite press release |title=Novo Nordisk A/S: Ozempic (semaglutide) approved in the EU for the treatment of type 2 diabetes |date=9 February 2018 |publisher=Novo Nordisk A/S |url=https://globenewswire.com/news-release/2018/02/09/1338393/0/en/Novo-Nordisk-A-S-Ozempic-semaglutide-approved-in-the-EU-for-the-treatment-of-type-2-diabetes.html |access-date=19 August 2018 |url-status=live |archive-url=https://web.archive.org/web/20190402075511/https://www.globenewswire.com/news-release/2018/02/09/1338393/0/en/Novo-Nordisk-A-S-Ozempic-semaglutide-approved-in-the-EU-for-the-treatment-of-type-2-diabetes.html |archive-date=2 April 2019 |via=GlobeNewswire}}</ref> in March 2018 in Japan,<ref>{{cite press release |title=Ozempic approved in Japan for the treatment of type 2 diabetes |date=23 March 2018 |publisher=Novo Nordisk A/S |url=https://www.globenewswire.com/news-release/2018/03/23/1449172/0/en/Ozempic-approved-in-Japan-for-the-treatment-of-type-2-diabetes.html |access-date=2 April 2019 |url-status=live |archive-url=https://web.archive.org/web/20190402081052/https://www.globenewswire.com/news-release/2018/03/23/1449172/0/en/Ozempic-approved-in-Japan-for-the-treatment-of-type-2-diabetes.html |archive-date=2 April 2019 |via=GlobeNewswire}}</ref> and in August 2019 in Australia.<ref name=\"AusPAR: Semaglutide\">{{cite web |date=2 December 2020 |title=AusPAR: Semaglutide |url=https://www.tga.gov.au/auspar/auspar-semaglutide |url-status=live |archive-url=https://web.archive.org/web/20220224072457/https://www.tga.gov.au/auspar/auspar-semaglutide |archive-date=24 February 2022 |access-date=23 February 2022 |website=Therapeutic Goods Administration (TGA)}}</ref><ref name=\"TGA Ozempic\">{{cite web |title=Summary for ARTG Entry:315107 Ozempic 1 mg semaglutide (rys) 1.34 mg/mL solution for injection pre-filled pen |url=https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=315107 |url-status=live |archive-url=https://web.archive.org/web/20220224072340/https://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=315107 |archive-date=24 February 2022 |access-date=6 June 2021 |website=Therapeutic Goods Administration (TGA)}}</ref>\n\nIn September 2019, a version which can be taken by mouth (Rybelsus) was approved for medical use in the United States,<ref>{{cite web |date=10 June 2020 |title=Drug Approval Package: Rybelsus |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213051Orig1s000TOC.cfm |url-status=live |archive-url=https://web.archive.org/web/20201102161121/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213051Orig1s000TOC.cfm |archive-date=2 November 2020 |access-date=26 September 2020 |publisher=U.S. [[Food and Drug Administration]] (FDA)}}</ref> and in the European Union in April 2020.<ref name=\"Rybelsus EPAR\">{{cite web |date=29 January 2020 |title=Rybelsus EPAR |url=https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus |url-status=live |archive-url=https://web.archive.org/web/20200814215223/https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus |archive-date=14 August 2020 |access-date=26 September 2020 |website=[[European Medicines Agency]] (EMA)}}</ref>\n\nIn June 2021, a higher-dose injection version sold under the brand name Wegovy was approved by the US [[Food and Drug Administration]] as [[anti-obesity medication]] for long-term weight management in adults.<ref name=\"Wegovy FDA label\"/>\nIn November 2021, the [[Committee for Medicinal Products for Human Use]] (CHMP) of the [[European Medicines Agency]] (EMA) recommended to grant a [[marketing authorization]] to Wegovy.<ref name=\"Wegovy : Pending EC decision\" /> to Novo Nordisk A/S.<ref name=\"Wegovy : Pending EC decision\">{{cite web |date=11 November 2021 |title=Wegovy : Pending EC decision |url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/wegovy |url-status=live |archive-url=https://web.archive.org/web/20211113052426/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/wegovy |archive-date=13 November 2021 |access-date=13 November 2021 |website=European Medicines Agency}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> In January 2022, Wegovy was approved for medical use in the European Union.<ref name=\"Wegovy EPAR\">{{cite web |date=11 November 2021 |title=Wegovy EPAR |url=https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy |url-status=live |archive-url=https://web.archive.org/web/20220702222728/https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy |archive-date=2 July 2022 |access-date=11 March 2022 |website=European Medicines Agency}}</ref> In the US, Wegovy has a list price of $1,349.02 per month per ''The New York Times'', suggesting that because of the [[Medication costs|high costs]] many people \"who could most benefit from weight loss may be unable to afford such expensive drugs\".<ref name=\"nyt-04-28\">{{cite news | vauthors = Kolata G |title=Patients Taking Experimental Obesity Drug Lost More Than 50 Pounds, Maker Claims |url=https://www.nytimes.com/2022/04/28/health/obesity-drug-eli-lilly-tirzepatide-wegovy.html |access-date=13 May 2022 |work=The New York Times |date=28 April 2022}}</ref>\n\n=== 2022 shortages ===\nIn May 2022, a shortage of semaglutide/Ozempic was reported in Australia as a result of an increase in prescriptions for weight loss in non-diabetic patients (off label use).<ref>{{cite web |date=27 May 2022 |title=Semaglutide shortage prompts caution around off-label prescribing |url=https://archive.ph/D41ex |url-status=live |archive-url=https://web.archive.org/web/20220901054509/https://archive.ph/D41ex |archive-date=1 September 2022 |access-date=1 September 2022 |website=news GP |vauthors=Liotta M}}</ref> This shortage resulted in many people with type 2 diabetes being unable to access the drug, so the [[Therapeutic Goods Administration|Australian Therapeutic Goods Administration]], along with Novo Nordisk, sent out guidelines to all health professionals, reminding them that people with type 2 diabetes needed to be prioritised in terms of supply. Updated guidelines were released in August 2022.<ref>{{cite web |title=Joint statement: Prioritisation of semaglutide (Ozempic) supply for people with type 2 diabetes during shortage |url=https://archive.ph/nqcwx |url-status=live |archive-url=https://web.archive.org/web/20220901053810/https://archive.ph/nqcwx |archive-date=1 September 2022 |access-date=1 September 2022 |website=Therapeutic Goods Administration (TGA) }}</ref>\n\nIn September 2022, shortages were also reported in the United States.<ref name=\"JensenWheeler2022\">{{cite web |last1=Jensen |first1=Leslie |last2=Wheeler |first2=Michelle |title=Current Drug Shortages : Semaglutide Injection |url=https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=813 |url-status=live |archive-url=https://web.archive.org/web/20220911170116/https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=813&loginreturnUrl=SSOCheckOnly |archive-date=11 September 2022 |access-date=11 September 2022 |website=American Society of Health System Pharmacists | name-list-style=vanc }}</ref> In the same month, rival [[Eli Lilly and Company|Eli Lilly]] stated in its quarterly investors call that it was working \"around the clock\" to ensure adequate supply of its rival GLP-1 agonist [[tirzepatide]] (Mounjaro).<ref name=\"Stanton2022\">{{cite news |last1=Stanton |first1=Dan |date=12 August 2022 |title=Lilly working 'around the clock' to ensure Mounjaro supply |work=Bioprocess Insider |url=https://bioprocessintl.com/bioprocess-insider/facilities-capacity/lilly-working-around-the-clock-to-ensure-mounjaro-supply/ |url-status=live |access-date=11 September 2022 |archive-url=https://web.archive.org/web/20220909010024/https://bioprocessintl.com/bioprocess-insider/facilities-capacity/lilly-working-around-the-clock-to-ensure-mounjaro-supply/ |archive-date=9 September 2022}}</ref>\n\n== Research ==\nIn 2021, semaglutide was found to be inferior to [[tirzepatide]] when used once weekly as add-on therapy to metformin in people with type 2 diabetes (SURPASS-2), in both endpoints of reduction in [[glycated hemoglobin|A1C]] and body weight, with a roughly similar safety profile.<ref>{{cite journal |last10=SURPASS-2 Investigators |vauthors=Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, Liu B, Cui X, Brown K |date=August 2021 | display-authors=6 |title=Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes |journal=The New England Journal of Medicine |volume=385 |issue=6 |pages=503\u2013515 |doi=10.1056/NEJMoa2107519 |pmid=34170647 |doi-access=free |title-link=doi |s2cid=235635529}}</ref><ref>{{cite web |date=27 June 2021 |title='Stunning' Twincretin Beats Semaglutide in Type 2 Diabetes |url=https://www.medscape.com/viewarticle/953825 |url-status=live |archive-url=https://web.archive.org/web/20210703032452/https://www.medscape.com/viewarticle/953825 |archive-date=3 July 2021 |access-date=30 June 2021 |publisher=Medscape Medical News > Conference News > ADA 2021}}</ref>\n\nA 2014 meta-analysis including a small number of patients found that semaglutide may be effective in lowering liver enzymes ([[transaminitis]]) and improving certain radiologically observed<ref name=\"Lee 2014 p=7392\">{{cite journal |vauthors=Lee SS, Park SH |date=June 2014 |title=Radiologic evaluation of nonalcoholic fatty liver disease |journal=World Journal of Gastroenterology |publisher=Baishideng Publishing Group Inc. |volume=20 |issue=23 |pages=7392\u20137402 |doi=10.3748/wjg.v20.i23.7392 |pmc=4064084 |pmid=24966609 |doi-access=free |title-link=doi }}</ref> features of metabolic-dysfunction\u2013associated fatty-liver disease ([[MAFLD]]).<ref>{{cite journal |vauthors=Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M |date=June 2022 |title=Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis |journal=Diabetes & Metabolic Syndrome |volume=16 |issue=6 |pages=102539 |doi=10.1016/j.dsx.2022.102539 |pmid=35709586 |s2cid=249584781}}</ref>\n\n== References ==\n{{reflist}}\n\n== External links ==\n* {{cite web |title=Semaglutide |url=https://druginfo.nlm.nih.gov/drugportal/name/semaglutide |website=Drug Information Portal |publisher=U.S. National Library of Medicine}}\n* {{cite web |title=Semaglutide |url=https://medlineplus.gov/druginfo/meds/a619057.html |website=MedlinePlus}}\n\n{{Oral hypoglycemics and insulin analogs}}\n{{Portal bar | Medicine}}\n\n[[Category:Antiobesity drugs]]\n[[Category:Glucagon-like peptide-1 receptor agonists]]\n[[Category:Peptide hormones]]"}